Metabolon Publishes Book Chapter Describing its Analytical Software


Metabolon Publishes Book Chapter Describing its Analytical Software

RESEARCH TRIANGLE PARK, N.C. (February 29, 2012) — Metabolon, Inc., a diagnostics and services company offering the industry’s leading biochemical profiling technology, announces the publication of "Software Techniques for Enabling High-Throughput Analysis of Metabolomic Datasets" in the book Metabolomics, ISBN 978-953-51-0046, edited by Ute Roessner and published by the open-access publisher, InTech. The book chapter describes software and computational tools developed by Metabolon to quickly and accurately process, analyze and interpret metabolomics data in a high-throughput environment.

The use of metabolomics to answer a variety of biological questions has increased dramatically over the last few years. Metabolomics analysis requires accurate and sensitive instrumentation (LC/MS, GC/MS, NMR, CE, etc.) to generate high-quality data that can be easily and rapidly analyzed. While instrumentation holds a critical role, processing the massive amounts of data generated by a metabolomics experiment is a major rate-limiting step. Metabolon has developed a suite of software and computational tools that play an important and direct role in the ability to process, analyze, and interpret metabolomics data. Through the implementation of these techniques the biochemicals in an experimental sample can be quickly and accurately identified which enables biochemical interpretation of the results and facilitates the understanding of biological mechanisms and modes of action.

Copies of the chapter can be accessed through the InTech link:

About Metabolon
Metabolon, Inc. has advanced the field of metabolomics by pioneering and patenting the industry’s leading biochemical biomarker discovery and profiling platform. It has developed the technology to quickly identify and measure all of the biochemicals in a biological sample through its proprietary global processing method. Through the generation and interpretation of data, this method provides a precise understanding of disease etiology and drug action, and advances personalized medicine beyond what genomics and other approaches can promise. Metabolon’s expertise is being embraced by a wide range of pharmaceutical, biotechnology, food and agricultural companies. Metabolytics, its biomarker discovery and analysis business, has completed over 350 client studies and processed over 50,000 samples for customers in 2011 alone. Building on its expertise in biochemistry understanding, Metabolon is also developing proprietary diagnostic tests to determine and track disease progression. For more information about Metabolon, please visit or contact Matt Zaske at or 919-595-2200.

Media Contact:
Mackenzie Mills